Returns Based on a $100,000 Investment

Transcription

1 A Leading Developer of Stem Cell Treatment Centers Fact Sheet 2016 Bioscience Americas, LLC Fund Data: Series 1: $15,000,000 Minimum Investment: $25,000 Type: Holdings: ) Investor Benefits: Private placement State-of-the-art stem cell treatment centers in the U.S. and Latin America 31% average annualized returns* Consistent cash flow paid quarterly Cash payout upon sale of centers to institutional investor or IPO projected to generate up to 10X ROI within 4 to 5 years Early cash-out option in 24 months, investors may elect cash-out and to receive their principal, plus pro-rata share of profits to date, paid-in-full Tax deferral through investment in self-directed IRA and 401(k) plans Compatible with 1031 exchange transactions (restrictions apply) As a recognized leader in developing, marketing, and managing stem cell treatment centers, Bioscience Americas is already taking advantage of the latest ground-breaking advancements in stem cell therapies to: Treat sports-related and orthopedic injuries, such as to knees and hips. These are the same treatments featured in the media that professional athletes are receiving to heal more quickly from injuries and surgeries. Treat life-threatening and debilitating diseases including Alzheimer s disease, Parkinson s disease, leukemia, and many other conditions. These advanced therapies can even help regenerate spinal cord cells to help paralyzed patients improve their quality of life. With a booming market for healthcare worldwide, soaring demand for medical care, and a rapidly aging population, Bioscience Americas is developing a global network of stem cell treatment centers to generate high income creating a pre-ipo opportunity to offer exceptional returns. About Proven track record 4,000 patients successfully treated since 2011 Awarded more than $400 million in research grants from government agencies such as NIH, and private organizations including the Christopher Reeve Foundation Established associations with leading research centers including UCLA, Harvard Medical School, the Salk Institute for Biological Studies, and many others International partnership the Global Institute of Stem Cell Therapy and Research (GIOSTAR), known as the global leaders in Stem Cell Technology 9 clinics already in development or under management Investment Strategy Develop state-of-the-art stem cell therapy centers in strategic locations in the U.S. and Latin America Meet the growing demand for treatment in underserved markets to generate high income, with quarterly distributions to investors Exit strategy, resell high-performing treatment centers at a significant profit to institutional investors or take the company public through an IPO Returns Based on a $100,000 Investment Avg. Years 2016 *Projections 2017 based 2018 on current target prospects Total Annual Exit 4 to 5 years THESE PROJECTIONS ARE PRESENTED FOR ILLUSTRATIVE Returns PURPOSES ONLY AND DO NOT Cash REPRESENT -- $4k A GUARANTEE $16k $48k Flow OF $87k FUTURE $155k RETURNS. 31% Projecting 4X to 10X ROI Through sale of company or assets to large ROI % -- 4% 16% 48% 87% 155% company, institutional investor or IPO THESE PROJECTIONS ARE PRESENTED FOR ILLUSTRATIVE PURPOSES ONLY AND DO NOT REPRESENT A GUA RANTEE OF FUTURE RETURNS. THIS IS NOT AN OFFER TO SELL A SECURITY OR A GENERAL SOLICITATION. AN OFFER TO SELL A SECURITY ONLY MAY BE MADE BY A PRIVATE PLACEMENT MEMORANDUM TO PRE-EXISTING SOPHISTICATED AND/OR ACCREDITED INVESTORS WHERE PERMITTED BY LAW. THIS CONTENT IS PROVIDED FOR GENERAL INFORMATIONAL PURPOSES ONLY. NOTHING HEREIN SHALL BE CONSTRUED AS TAX, LEGAL, INVESTMENT OR ACCOUNTING ADVICE. THERE ARE NO GUARANTEES THAT ANY RETURNS WILL BE ACHIEVED. POTENTIAL INVESTORS SHOULD CONSULT THEIR ATTORNEY, ACCOUNTANT, AND FINANCIAL ADVISORS BEFORE INVESTING.

2 A Leading Developer of Stem Cell Treatment Centers Table As on seen back on: that 100+ Years Combined Experience 9 Clinics In Development & Under Management Proven Track Record Management Team Eric Stoffers, CEO With more than fifteen years of business and executive experience, Mr. Stoffers has taken on key leadership roles in many business ventures with experience managing commercial properties including a medical resort facilities in Mexico and a major U.S. restaurant chain. His expertise incudes sales, outsourcing, recapitalization, acquisition, dispositions, and development. He holds a degree in Business Administration and from Northern Arizona University. Dr. Anand Srivastava, PhD Dr. Srivastava enjoys a worldwide reputation as one of the leading experts in stem cell biology, gene therapy, and clinical research. His work has been published in scientific journals cited extensively by other scientists and has been recognized by his peers through highly prestigious awards, plus invitations to present his work at international scientific conferences. He now leads scientific research at various institutions including UCLA and the Salk Research Institute, among others. A Ground-Floor Opportunity: The Rapidly Surging Demand for Stem Cell Therapy Offers Exceptional Investment Potential Here s why: As the world population continues to age, the number of people over the age of 60 will reach 1 billion by 2020 doubling in only the last 25 years Global spending for healthcare, a sector little impacted by economic recessions, will reach $12 trillion by New stem cell treatments for many diseases are not available in the U.S., but many insurance companies will pay for these treatments The U.S. medical tourism market, already $55 billion per year, continues to grow. Stem cell therapies for orthopedic & sports related treatments will reach $42 billion by 2018 and $51 billion by Opening 4 new strategically located clinics in 2017 Meeting the needs of an enormous underserved market Testimonials This is the group to invest with. The Bioscience Americas Team has delivered well beyond our expectations. John & Nancy M., Investors I cannot speak highly enough about Eric and his team. I used my self-directed IRA to invest and they were there to walk me through the entire process. David C., Physician I ve worked with Eric and his team for years. They re always a step ahead of the curve. Jeffrey J., Real Estate Broker For more information: Call: info@bioscienceamericas.com This is a rare opportunity to invest with us as we build new stem cell treatment centers, develop them to generate high income, and then sell them at a substantial profit to larger institution or go public via an IPO. Eric Stoffers, CEO, Bioscience Americas

3 SOLUTIONS FOR A HEALTHIER WORLD THROUGH ADVANCED STEM CELL THERAPIES PROSPECTUS $15,000,000 (1,500 Units at $10,000 per Unit) Minimum Subscription $25,000 A PRIVATE OFFERING TO ACCREDITED INVESTORS ONLY THIS MEMORANDUM IS FOR OVERALL INFORMATION PURPOSES ONLY. THIS IS NOT AN OFFER TO SELL A SECURITY OR A GENERAL SOLICITATION. AN OFFER TO SELL A SECURITY MAY BE MADE ONLY BY A PRIVATE PLACEMENT MEMORANDUM TO PRE-EXISTING SOPHISTICATED AND/OR ACCREDITED INVESTORS WHERE PERMITTED BY LAW. PERSONS INTERESTED IN INVESTING AND WHO ARE QUALIFIED TO INVEST, SHOULD CONTACT THE COMPANY AT TO OBTAIN FURTHER INFORMATION.

4 Bioscience Americas, a leading developer of stem cell treatment centers, was founded to bring adult stem cell-based regeneration and rejuvenation treatment to patients worldwide. The company is the international development partner of the Global Institute of Stem Cell Therapy and Research (GIOSTAR), recognized as the world s leading stem cell research consortium, dedicated to creating cures for life-threatening autoimmune diseases and healing injuries through the latest innovations in stem cell therapies. With a proven-track-record and more than 100 years of combined experience, Bioscience Americas leadership has been featured on CNBC, Fox News, Bloomberg, and The Wall Street Journal. Since 2011, more than 4,000 patients have successfully treated at the company s research facility at the UC San Diego Medical Center and flagship hospital in India. Now partnering with investors to expand its market in the U.S., Canada and Latin America, Bioscience America s investment strategy is to build, develop, and market high-income producing stem cell therapy clinics in these markets then resell these high income generating clinics to a larger organization or through an IPO. This strategy offers investors a low-risk, high-potential-reward opportunity.

5 Executive Team Eric Stoffers, CEO Mr. Stoffers is an internationally recognized author, investment manager, and philanthropist. With more than fifteen years of business and executive experience, Mr. Stoffers has taken on key leadership roles in many business ventures managing commercial properties including medical resort facilities in Mexico and a major U.S. restaurant chain. Eric s track record demonstrates proven success at scaling businesses and increasing investor and shareholder value. His expertise includes mergers & acquisitions, recapitalization, and development. He holds a degree in Business Administration from Northern Arizona University. Dr. Anand Srivastava, Ph.D. Chief Scientific Officer, GIOSTAR Dr. Srivastava is a world-renowned expert in stem cell biology, gene therapy, and clinical research. His work has been published in widely respected scientific journals cited extensively by other scientists and has been recognized by his peers through highly prestigious awards, plus invitations to present his work at international scientific conferences. He now leads scientific research at various institutions including University of California San Diego, UCLA, and the Salk Research Institute, among others. Dr. Leslie Miller Dr. Miller is an internationally renowned cardiologist and expert in the field of heart failure and transplantation. He has served as an investigator in over one hundred clinical trials and has refocused his research on the use of stem cells to treat heart disease. Dr. Miller previously served as the Director of the cardiac programs at Georgetown University School of Medicine, Washington Hospital Center as well as the University of Minnesota. He has received numerous awards from both fellows and residents, including teacher of the year in internal medicine and the Proctor Harvey Chair.

6 Investment Overview Bioscience Americas, LLC Purpose of Fund: Offer accredited investors low-risk, high potential reward investment opportunities to capitalize on the emerging stem cell therapy market Manager Bioscience Capital, LLC Initial Offering $15,000,000 Number of Units / Price per Unit 1,500 ($10,000 per Unit) Minimum Subscription $25,000 Use of Proceeds Build and develop state-of-the-art stem cell therapy clinics in the U.S., Canada, and Latin America Projected Returns 31% average annualized returns over 5 years Fund Objectives Build, develop, and market high-income producing stem cell therapy clinics in strategic locations in partnership with leading global stem cell research institute GIOSTAR. Distribute cash flow as quarterly payments to investors with expected 31% average annualized returns over 5 years. Exit strategy: Resell high-income producing clinics to a large organization or issue public IPO with a projected ROI of up to 10X within 4 to 5 years. 24-Month Cash Out Option Investors may choose to exercise an option to cash out after 24 months and receive principal plus pro-rata share of profits to date, paid-in-full.

7 Executive Summary Bioscience Americas was founded to capitalize on the emerging demand for stem cell therapy by building and developing high-income producing treatment clinics, then sell these clinics for a significant profit. Our investment strategy: o Develop high income producing state-of-the-art stem cell therapy clinics in strategic locations with our development partner GIOSTAR, known worldwide as leaders in stem cell treatment technologies o Provide cash flow to investors through quarterly distributions o Resell high-performing and high-producing clinics to a larger organizations or take company public by issuing IPO Bioscience Americas and its partners have invested their own time and money for research, detailed studies, and due diligence for each clinic to identify optimum opportunities that minimize risk and offer the potential for significant returns. Investment Allocation An excellent fit for the medium- to low-risk allocation of your investment portfolio

8 A Proven Track Record More than 100 years of combined experience. 9 clinics in development, and under management. Proven expertise in developing and operating profitable stem cell therapy clinics. Since 2011, successfully treated more than 4,000 patients. Development partner GIOSTAR recognized as one of the world s leading stem cell research institutions with 15 years of experience and scientists associated at institutions including: UC San Diego UCLA UC Irvine Vanderbilt University Harvard University Salk Institute University of California Medical Center Awarded more than $400 million in research grants, endowment contributions, and legislative appropriations. Investor Benefits: Average annual return of 31% Quarterly cash flow distributions Option to cash out in 24 months Exit strategy of reselling high-income producing clinics to large company or issue an IPO This is a rare opportunity to invest with us as we build new stem cell treatment centers, develop them to generate high income, and then sell them at a substantial profit to larger institutions or go public via an IPO. - Eric Stoffers, CEO, Bioscience Americas

9 Projected Returns on Investment Summary Summary o 31% average annualized returns o 87% distribution in year 5 o Up to 10X ROI by year 5 based on exit strategy to resell to large company, institutional investor or via IPO o Cash out option: Investors may cash out in 24 months and receive their principal plus pro-rata share of profits, paid-in-full THESE PROJECTIONS ARE PRESENTED FOR ILLUSTRATIVE PURPOSES ONLY AND DO NOT REPRESENT A GUARANTEE OF FUTURE RETURNS. This is not an offer to sell a security or a general solicitation. An offer to sell a security can only be made by a private placement memorandum to preexisting sophisticated and/or accredited investors where permitted by law. This content is provided for general informational purposes only. Nothing herein shall be construed as tax, legal, investment or accounting advice. There are no guarantees that any returns wi ll be achieved. Potential investors should consult their attorney, accountant, and financial advisors before investing.

10 Frequently Asked Questions Does Bioscience Americas use embryonic stem cells? Bioscience Americas does not use embryonic stem cells in our treatments or therapies. We use a patient s own autologous, or adult, stem cells that we source from the patient s fatty tissue or bone marrow. Our scientists take the patient s stem cells, multiply them by the millions, and through a process called induced pluripotent convert them to the embryonic stage and direct the cells to where in the body they want them to go. What is Bioscience Americas track record? With 100+ years of combined experience, Bioscience Americas executives have earned millions of dollars in investor returns over the past 20 years. Since 2011, Bioscience Americas and research partner GIOSTAR have treated 4,000 patients through the latest innovations in stem cell therapies to cure life-threatening diseases and heal debilitating injuries and has been awarded more than $400 million in research grants, endowment contributions, and legislative appropriations. How do I get started? Call our Investor Relations Department at or info@bioscienceamericas.com. We ll answer your questions and discuss your financial goals to determine if this is an appropriate investment to meet those goals. If you prefer to meet in person, we ll be happy to schedule a meeting with you in our Phoenix or New York office. What type of return can I expect on my investment? We project an average annual return on investment of 31% over the first 5 years. When do I start receiving quarterly dividend checks? Quarterly dividend payments are projected to begin in How long before my principal is paid back in full? Based on our projections we estimate that by year 4 or 5, quarterly dividends will represent full return of principal plus a substantial ROI. Contact us for further details. Can I cash out early? Yes, investors have the option to cash out in 24 months to receive return of principal plus their pro-rate share of profits to date.

11 Frequently Asked Questions Continued What is Bioscience America s Exit Strategy? After building and developing high-income-producing stem cell therapy clinics, these clinics will be sold to a larger company or by issuing a public IPO. Why invest with Bioscience Americas? Exceptional returns through consistent quarterly dividends Proven track record in developing profitable clinics and successfully treating patients Experienced leadership well positioned to take advantage of a growing market, minimize risk, and earn significant returns Excellent growth potential with up to 10X ROI projected upon sale to a larger company or initial public offering Leveraging the latest technology already funded in part through $400 million awarded through research grants by government and private organizations Recession-resistant healthcare industry sector What Our Investors Say This is the group to invest with. The Bioscience Americas Team has delivered well beyond our expectations. -- John and Nancy M. - Investors I cannot speak highly enough about Eric and his team. I used my self-directed IRA to invest and they were there to walk me through the entire process. -- David C., MD I ve worked with Eric and his team for years. They re always a step ahead of the curve. Now partnering with GIOSTAR, I m confident they will help positively impact thousands of people s lives with their ground-breaking medical breakthroughs and I m honored to be a part of it. -- Jeffrey J. Real estate broker

12 Invest with Bioscience Americas Expertise, experience and proven-track-record to help investors capitalize on high-potential-reward opportunities in a rapidly expanding healthcare market. Call our Investor Relations department today! info@bioscienceamericas.com 2122 E Highland Avenue, Suite 265 Phoenix, AZ